Epac, a positive or negative signaling molecule in cardiovascular diseases

Area of Science:

• Molecular Biology
• Cardiovascular Research
• Cellular Signaling

Background:

• Cardiovascular diseases (CVDs) are a leading cause of mortality and morbidity globally.
• The complex pathogenesis of CVDs remains incompletely understood, highlighting the need for further research.
• Mitochondrial function and cAMP signaling are critical in cardiovascular physiology and pathology.

Purpose of the Study:

• To systematically review the mechanisms by which Epac (Exchange protein directly activated by cyclic AMP) influences cardiovascular diseases.
• To explore Epac's role in various CVD-related pathways, including ion regulation, cardiac hypertrophy, fibrosis, apoptosis, and angiogenesis.
• To provide insights for novel therapeutic strategies and targeted drug development for CVDs like arrhythmia and heart failure.

Main Methods:

• Systematic review and discussion of existing scientific literature on Epac and CVDs.
• Analysis of Epac's involvement in diverse cellular and molecular pathways relevant to cardiovascular function.
• Synthesis of current understanding regarding Epac's physiopathological roles in the heart.

Main Results:

• Epac, a key cAMP effector, is implicated in multiple CVD mechanisms.
• Epac influences critical cardiovascular processes such as cardiomyocyte survival, cardiac remodeling, and vascularization.
• While some mechanisms show inconsistencies, they underscore the complexity and significance of Epac's functions in CVD.

Conclusions:

• Epac is a significant molecular target for understanding and treating cardiovascular diseases.
• Further research into Epac's diverse roles can pave the way for innovative therapeutic interventions.
• The complexity of Epac signaling necessitates continued investigation for effective drug discovery in cardiology.